Biotech and Pharmaceutical ManagementImmersion Program

Sean Nicholson is a professor in the Department of Policy Analysis and Management (PAM) at Cornell University, the director of the Sloan Program in Health Administration, and a research associate at the National Bureau of Economic Research. Prior to joining the PAM department in 2004, Professor Nicholson was a faculty member in the Health Care Systems Department at The Wharton School of the University of Pennsylvania. He worked for four years as a management consultant with APM and taught high school for two years before enrolling in graduate school. Professor Nicholson received a B.A. from Dartmouth College in 1986 and a Ph.D. in economics from the University of Wisconsin-Madison in 1997.

 Tanzeem Choudhury is a professor in Computing and Information Sciences at Cornell Tech, where she holds the Roger and Joelle Burnell Chair in Integrated Health and Technology. At Cornell, she directs the People-Aware Computing Group and leads the Precision Behavioral Health Initiative, focused on advancing the future of technology-assisted well-being. Professor Choudhury cofounded HealthRhythms Inc, a company whose mission is to add a layer of behavioral health into all of healthcare. She is also the Senior Vice President of Digital Health at Optum Labs. Prior to Cornell, Professor Choudhury was an Assistant Professor in Computer Science at Dartmouth College. She received her Ph.D. from the MIT Media Laboratory.

Professor Choudhury has received the NSF CAREER award (2008), TR35 award (2008), TED fellowship (2009), PopTech Science fellowship (2010), Kavli fellowship (2011), Ubicomp 10-Year Impact Award (2016, 2022). She has been elected as an ACM Fellow (2021) and inducted into the ACM SIGCHI Academy (2022).

Robert Langer is one of 12 Institute Professors at the Massachusetts Institute of Technology (MIT); being an Institute Professor is the highest honor that can be awarded to a faculty member. In 1970, Dr. Langer received his B.S. with distinction in Chemical Engineering and was awarded his Sc.D. from MIT in 1974. He has written over 1,500 articles, which have been cited over 383,000 times; his h-index of 307 is the highest of any engineer in history and the second highest of any individual in any field. Dr. Langer’s patents have been licensed or sublicensed to over 400 companies; he is a cofounder of a number of companies, including Moderna. Dr. Langer served as chairman of the FDA’s Science Board (its highest advisory board) from 1999 to 2002. 

Dr. Langer is the recipient of over 220 awards, including both the United States National Medal of Science and the United States National Medal of Technology and Innovation (he is one of three living individuals to have received both these honors), Cornell Entrepreneur of the Year, the Charles Stark Draper Prize (often called the Engineering Nobel Prize), Queen Elizabeth Prize for Engineering, Albany Medical Center Prize, Breakthrough Prize in Life Sciences, Kyoto Prize, Wolf Prize for Chemistry, Millennium Technology Prize, Priestley Medal (the highest award of the American Chemical Society), Gairdner Prize, Hoover Medal, Dreyfus Prize in Chemical Sciences, BBVA Frontiers of Knowledge Award in Biomedicine, and the Balzan Prize. Dr. Langer holds 40 honorary doctorates, including Harvard, Yale, Columbia, and Northwestern, and he has been elected to the National Academy of Medicine, the National Academy of Engineering, the National Academy of Sciences, and the National Academy of Inventors.

 Joydeep Ganguly is Senior Vice President of Corporate Operations at Gilead Sciences. In his current role, Mr. Ganguly is accountable for several strategic functions, including corporate engineering, capital and infrastructure strategy, corporate real estate, risk management, operations research, and global procurement. Serving as the Chief Sustainability Officer for the organization, he also leads Gilead’s environmental sustainability strategies globally. He is a member of the company’s executive ESG committee as well as a board member of the Gilead Foundation. Prior to Gilead, Mr. Ganguly spent 10 years at Biogen in roles of increasing responsibility in the areas of technical operations, manufacturing, and supply chain. In his role as Vice President and General Manager of Biogen’s global manufacturing network, he oversaw the company’s multiscale biologics and small-molecule operations, and he led general operations for the company’s presence in North Carolina.

 A past board member of the North Carolina Biosciences Organization (NCBIO) and the North Carolina Museum of Life and Sciences, Mr. Ganguly currently serves on the Board of Directors of Bay Area Council, Biocom, and Science from Scientists, and he is a trustee at Town School for Boys. He earned an M.S. in Electrical Engineering from the University of Notre Dame, an MBA from North Carolina State University, and an MHA from Cornell University. Mr. Ganguly was recently recognized by the National Diversity Council as a Top 50 Diverse Leader in California and was awarded the Leadership Excellence Award by the California Diversity Council.

 Arnaub Chatterjee is Chief Product and Solutions Officer at TriNetX, a health technology platform focused on improving clinical research, study design, safety, and clinical trial recruitment. He also serves as Senior Advisor at the Carlyle Group in evaluating investments in the life sciences and healthcare sectors. Additionally, Mr. Chatterjee is passionate about teaching and is a member of the faculties in the Department of Health Care Policy at Harvard Medical School and in the Department of Policy Analysis and Management at Cornell University.

Prior to TriNetX, Mr. Chatterjee was Senior Vice President and head of Medidata AI, the data sciences business of Medidata Solutions. At Medidata, he was building novel software and data science solutions in clinical, commercial, and imaging analytics for the life sciences industry.  Before his time at Medidata, Mr. Chatterjee was Associate Partner in the Pharmaceutical and Medical Products group at McKinsey & Company, where he supported clients on topics such as R&D strategy, portfolio prioritization, and go-to-market. He also held roles as Director of Data Science and Insights within Merck’s Center for Real-World Evidence and as a technology advisor in the Obama administration in the Department of Health and Human Services (HHS). 

Mr. Chatterjee’s work has been published in multiple peer-reviewed journals such as the Harvard Business Review and Nature, and he has presented at conferences ranging from South by Southwest to the American College of Cardiology. He serves as an advisor and board member to a number of organizations, including the World Economic Forum’s Council for Biotechnology; BioSpring, a life sciences growth equity firm; and CityPods, a solution to scale temporary housing. Mr. Chatterjee holds graduate degrees in health administration (MHA) and public administration (MPA) from Cornell University, and he received his undergraduate degree from the University of Michigan.

Saif is a member of the Healthcare practice, with deep expertise in the use of advanced analytics across the health care ecosystem.
Saif has worked with biotechnology, large pharmaceutical companies, medical technology manufacturers, provider systems, payors, academic organizations, government entities, not for profits, and investment groups in North America, Europe, and Asia.

Saif provides expertise in a broad range of topics in health care, including:

• Advanced analytics: Use of AI and machine learning in research and development and medical affairs in pharma, biotech, and med tech; provider AI use cases, including deployment and evaluation
• Strategy: Portfolio review, platform build, product launch, indication expansion, value and access
• Real world data: Development of RWD capabilities, programs, delivery of RWE insights
• Diligence: Evaluation of pre-clinical and clinical assets, research platforms, medical technology, digital health offerings for investment (seed to IPO) and acquisition
• Cardiometabolic disease: 130+ peer reviewed articles in cardiovascular disease, diabetes, and health services research, including professional position statements, national guidelines

Previous Work Experience:

• SVP Strategy at Cellarity, a $600M AI-enabled biotech in the Flagship Pioneering ecosystem
• Joint position as Global Head of Data and Analytics Innovation at Cigna and Express Scripts and Medical Director of Cigna Ventures
• Associate Principal and Medical Director, McKinsey & Company
• Lecturer, Yale University School of Medicine
• Education
• Internal medicine residency at Massachusetts General Hospital
• MD from Yale University School of Medicine
• PhD (epidemiology) from Yale University
• MPH (public health) from University of North Carolina at Chapel Hill School of Public Health
• AB (history, psychology, cognitive studies) from Cornell University

 Sandeep Duttagupta, Ph.D., is currently the Vice President of Global Pricing and Market Access at Alnylam. Dr. Duttagupta’s responsibilities include overseeing Alnylam’s pricing and access strategies for its entire portfolio, managing the global governance around access, and working closely with regional teams to maximize the value of their programs, and playing a key role in developing future innovative access programs per Alnylam’s Patient Access philosophy.  

Dr. Duttagupta has over 25 years of global industry and management consulting experience, specializing in global pricing and market access for biopharmaceutical products. Most recently he was a partner at DRG/Clarivate Consulting and Practice Lead for Global Pricing and Market Access. Dr. Duttagupta joined erstwhile DRG Consulting in 2018 and advised biopharmaceutical clients in their go-to-market pricing and patient access strategies across the U.S., Europe, Japan, China, and emerging markets. He worked with both government and private healthcare payers across the globe to help key pharma and biotech clients maximize access to patients for innovative medicines.

Prior to DRG/Clarivate, Dr. Duttagupta was at CBPartners, a NYC-based boutique life sciences strategy consulting firm specializing in value, access, and pricing, where he held the role of Senior Vice President of Business Development. During his tenure, he helped expand the firm’s business into a substantial number of new clients across various geographies. Prior to this, Dr. Duttagupta spent 17 years at Pfizer, across positions of increasing responsibility, first within Global and U.S. HEOR, then for 10 years in various Global Pricing and Market Access functions. His last position was as the Vice President of P&MA for Pfizer’s Emerging Market Business Unit, where he had the opportunity to reshape internal thinking and business models in low- to middle-income countries across Pfizer’s portfolio. Additionally, on behalf of PhRMA, Dr. Duttagupta was often the face of the pharmaceutical industry in shaping industry-friendly government policies in a large number of countries.

Dr. Duttagupta also serves as an Executive Board member for privately held Aquavit Pharmaceuticals and Celanese (NYSE: CE).

Stephanie A. Wisner co-founded the biotech start-up, Centivax, where she is now Chief Business Officer. She has also advised multiple biotech start-ups on business and commercialization strategy through her consulting business, BioVenture Advising LLC, and spent several years at ARCH Venture Partners. In 2022, she was named to the Forbes 30 Under 30 list for Healthcare. She completed her MBA at the University of Chicago Booth School of Business, with concentrations in finance, accounting, and entrepreneurship. She received her Bachelor’s Degree in chemistry and chemical biology from Cornell University and was awarded the Einhorn Discovery Research Grant for her independent research on cancer. Her book, Building Backwards to Biotech, was an Amazon #1 New Release in the category of Biotechnology. The book is currently taught as part of bioentrepreneurial programming at multiple top institutions, including Dartmouth College, Cornell University, and others. She is also an Entrepreneur-in-Residence at Cornell University. While she no longer gets as much time in the lab, she enjoys the travel and continuous learning this career involves. You can reach Stephanie at bioventureadvising.com.

Amy Mulderry is Senior Vice President and Chief Development Officer at Elevance Health, Inc. In this role, she leads the company’s inorganic growth strategy, including joint ventures and minority investments, mergers and acquisitions, and corporate integration. In 2022, the role of CFO for Carelon was added to her responsibilities. Prior to joining Elevance Health, Ms. Mulderry spent 20 years as a healthcare industry investor managing equity portfolios at top-tier asset management firms. 

Ms. Mulderry served as managing partner and portfolio manager for Tavio Capital LLC, where she managed a $600 million long/short equity healthcare hedge fund as a subadvisor to the Blackstone Equity Managed Account Platform and a healthcare-dedicated beta-neutral fund with a primary focus on healthcare services and medical device sectors. Ms. Mulderry also served in previous healthcare portfolio management roles with Citadel Global Equities, SAC Capital, Salomon Brothers Asset Management, and CIBC World Markets Corp. She earned her  Bachelor of Arts from Cornell University,

Emma Pierson is an Assistant Professor of Computer Science at the Jacobs Technion-Cornell Institute at Cornell Tech and the Technion, as well as a computer science field member at Cornell University. She holds a secondary joint appointment as an Assistant Professor of Population Health Sciences at Weill Cornell Medical College. Professor Pierson develops data science and machine learning methods to study inequality and healthcare. Her work has been recognized by best paper, poster, and talk awards, and with an NSF CAREER award, Rhodes Scholarship, Hertz Fellowship, Rising Star in EECS, MIT Technology Review 35 Innovators Under 35, and Forbes 30 Under 30 in Science. Professor Pierson’s research has been published at venues including ICML, KDD, WWW, Nature, and Nature Medicine, and she has written for The New York Times, FiveThirtyEight, Wired, and various other publications.

Paul Evans, PhD has worked in the pharmaceutical industry for over 30 years. He is currently President and CEO of Velocity Clinical Research, which owns and operates investigator sites across multiple therapeutic areas in the US and Europe. From a private equity start-up in 2018 Velocity has grown to be the largest SMO (Site Management Organisation) in the world under Paul’s leadership and is focused on solving the delays caused by the inherent inefficiencies of the clinical research process. This was particularly critical during Operation Warp Speed to develop the COVID19 vaccines in which Velocity contributed more patients than any other organization.
He started his career establishing and managing research sites in the UK and was a founder of one of the first European SMOs. Paul joined the CRO sector in 2005 building global site networks that partnered strategically rather than being selected tactically by the CRO and continued to work on innovative patient recruitment campaigns in some of the most challenging environments across all continents. In two of the world’s largest CROs he has led global functions that have included site intelligence, study start-up, feasibility, site contracting, patient recruitment and Investigator payments. Few people have had the opportunity to spend so much of their careers working both on the investigator and sponsor sides of the GCP divide and this breadth of experience gives him a unique insight into the challenges faced by the drug development industry.

Shawn Malloy is VP of Marketing at Curebase, a company that is reinventing decentralized clinical trials to help the vast majority of potential patients that currently cannot access clinical research. Curebase’s vision is that any patient, no matter where they are located, should be able to participate in clinical trials at home and with their own doctors to expand access to clinical trials to anyone who may benefit. Curebase seeks to break the long standing precedent of trial participation that predominantly focuses on large urban affluent research centers that lack representative populations of those afflicted by healthcare issues at large. This is made possible through a unique suite of tools, including all-in-one eClinical software and virtual research sites, designed to engage patients in clinical trials across all settings, be it at home, at their local clinic, or in other places in their community.

Shawn’s role at Curebase includes leading all B2B marketing efforts for the company brand and its positioning with prospective customers across Biotech, Pharma, and Med Device. Additionally, Shawn runs a patient recruitment service through Curebase focused on B2C marketing of individual studies the company run’s for its customers to patients of all kinds.

Shawn is an engineer by training earning his Bachelor’s and Masters in BioEngineering from Cornell University. He had spent the beginning of his career working in large pharma at companies like Amgen, Biogen, and AbbVie focused on product development and commercialization efforts. Since then, Shawn obtained his MBA from Boston University with a focus in healthcare marketing and made a pivot to working on sales and marketing of health tech. Shawn has a passion for understanding market needs in the healthcare industry, understanding customer personas and buying journeys, and transforming those insights into optimized positioning and promotional strategies.

Angela Hwang is the Chief Commercial Officer and President of the Global Biopharmaceuticals Business at Pfizer and a member of its Executive Leadership Team. She and her organization, comprised of over 26,000 colleagues, are responsible for delivering all 600 of Pfizer’s medicines and vaccines to patients in 185 countries. In 2022, more than 1.3 billion people received a Pfizer therapy that protected and improved their health. Under Angela’s leadership, Pfizer Biopharma generated $100 billion in 2022 revenues.

Pfizer’s Biopharma business addresses major global health priorities, including cancer, COVID-19, infectious diseases, inflammation & immunology, rare diseases, cardiovascular/metabolic disorders, and preventative care with vaccines. But Angela’s work goes beyond making medicines available. She is equally focused on creating and expanding collaborations with health insurers, governments, policymakers, and global health stakeholders around the world to come up with new and better ways to meet health challenges and make medicines accessible and affordable for all.

In 2020, Angela and Pfizer’s Biopharma team launched the world’s first COVID-19 vaccine and, one year later, the first oral antiviral treatment. Though vaccines often take many years to develop distribute, Angela and her team — inspired by a relentless focus on helping patients — made the impossible possible.

Angela’s commitment to health equity has deep roots. Her experience growing up as an Asian girl in South Africa during the apartheid era shaped her worldview. It helps explain why, after 27 years at Pfizer, she continues to find purpose and common cause with her Pfizer colleagues to bring more breakthroughs to patients, no matter who they are or where they live. Under Angela’s leadership, Pfizer launched An Accord for a Healthier World, a first-of-its-kind initiative to enable sustained, equitable access to all of Pfizer’s medicines and vaccines in 45 lower-income countries. The Accord has the potential to improve the health of 1.2 billion people and transform the healthcare ecosystem in those countries.

Beyond her work at Pfizer, Angela serves on the Board of Directors of UPS, the European Federation of Pharmaceutical Industries and Associations, the U.S. China Business Council, Cornell’s Johnson Graduate School of Management Advisory Council, and the Pfizer Foundation, which uses the power of philanthropy to improve global health.

Angela is consistently ranked among the world’s top leaders in healthcare and business by publications including Crain’s, Business Insider, Forbes, and Fortune, which placed her in the top 20 Most Powerful Women in Business three years in a row. Angela is also an honoree of A100, which recognizes the most impactful Asian American and Pacific Islander (AAPI) leaders. In 2021, she received the President’s Award from the National Diversity Council for championing diversity, equity, and inclusion. Cornell University named Angela a Robert S. Hatfield Economic Fellow in 2022. In 2023, she was recognized as a Ascend A-list Honoree for her professional achievements as an Asian American leader. Angela received her Bachelor of Science in Microbiology and Biochemistry from the University of Cape Town and her MBA from Cornell. Angela and her husband are proud parents of a teenage daughter and son. Angela is a fierce advocate for women’s leadership and sustainable global health equity. You can follow Angela on LinkedIn and on Instagram using @angelahwangpfizer.